Alphavirus vectors: development and potential therapeutic applications.
Alphaviruses are RNA enveloped viruses that are proving their value as expression vectors. They are particularly well-suited for this role as they are easily and quickly engineered and can be used to produce high levels of proteins of interest. A promising and important use is as vaccines against disease-causing agents such as HIV. The three alphaviruses now serving as vectors are Sindbis virus, Semliki Forest virus (SFV) and Venezuelan equine encephalitis (VEE) virus. Sindbis virus and SFV are well-known models for studies in molecular and cell biology; VEE virus is a human pathogen and had received some previous notoriety as a potential biological weapon. It is now becoming a potentially valuable vaccine vector. All three viruses are being tested as vaccines but, at present, only Sindbis virus and SFV have been considered for other uses. Sindbis virus vectors have been developed to screen libraries for the identification of new proteins and to devise sensitive assays to detect viruses more difficult to grow in culture. Both Sindbis virus and SFV vectors are serving as tools for fundamental studies in biology, examples include development in insects and analysis of protein functions in neuronal cells. In this article the replication strategy of alphaviruses and the different ways they can be engineered to serve as expression vectors is described. This provides an introduction to the ways these vectors have been used and illustrates the promise these vectors offer.
Schlesinger
S
S
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110-1093, USA. sondra@borcim.wustl.edu
D000524:Alphavirus / Q000235:genetics* / Q000302:isolation & purification / Q000472:pathogenicity / Q000502:physiology; D000818:Animals; D005814:Genes, Viral / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use*; D016679:Genome, Viral; D006378:Helper Viruses / Q000235:genetics / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D009928:Organ Specificity; D012367:RNA, Viral / Q000235:genetics; D012093:Replicon / Q000235:genetics; D014765:Viral Vaccines / Q000235:genetics / Q000627:therapeutic use; D019065:Virus Assembly; D014779:Virus Replication
D012367:RNA, Viral; D014765:Viral Vaccines